Sanofi to outsource antiinfectives R&...Evotec and Sanofi want to create an Evotec-led infectious disease open innovation R&D platform at Sanofis antiinfectives hub in Lyon. Talks are expected to close in H1/2018 with an option agre … more ➔
Heidelberg Pharma inks US$334m R&D co...Under an exclusive licence option agreement, Heidelberg Pharma will develop ATACs (alpha-amanitin antibody conjugates) for Magenta Therapeutics Inc. across several targeted conditioning programmes … more ➔
Investors keen to put money into AMR SMEsInvestments into new drugs to tackle antimicrobial resistance (AMR) are set to boost the participation of SMEs. At the 11th Berlin Conference on Life Sciences, two new financing initiatives, which focus … more ➔
Santheras idebenone not efficient in PPM...Swiss Santhera Pharmaceuticals EU-approved LHON treatment Raxone (idebenone) has failed to show clinical efficacy in another indication: After US and EU regulators rejected an extension of market approval … more ➔
Inhaled IL-4 halts neuron destruction in M... An US-German team has found a way to halt the inflammatory brain cell destruction in mice with multiple sclerosis (MS) without suppression of the human immune system. more ➔
Convert Pharmaceuticals SA closes €13.6m... Liège-based Convert Pharmaceuticals SA has been granted a total of €13.6m in equity and non-dilutive funding by investors Droia Oncology Ventures, Meusinvest and Spinventure, with non-dilutive … more ➔
Novo Holdings launches €135m fund to com...Novo Holdings has launched the REPAIR impact fund commissioned by the Novo Nordisk Foundation. The goal is to invest into early-stage drug developers with new concepts to fight antimicrobial … more ➔
Bavarian Nordic and AZ combine cancer jab... AstraZeneca (AZ) and Bavarian Nordic (BN) combine BNs cancer vaccine CV301 and AZs PD-L1 checkpoint blocker durvalumab in an investigator-sponsored trail to check synergistic effects in patients … more ➔
EMA recommends two orphan drugs for approv...The European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended three medicines, two thereof orphan drugs, at its February 2018 meeting. more ➔
Bioeconomy: Bringing in the publicEverybody wants green production. Bioeconomy progress, however, must become more visible to consumers and let the civil society get involved to ensure socially robust innovation and perception, according … more ➔
